Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease treatments, has announced its participation in two upcoming investor events in September 2025.

CEO Shalabh Gupta will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 8:30 a.m. ET, followed by another fireside chat at the Truist Securities Virtual event on September 17 at 10 a.m. ET. Webcasts will be available on the company's investor relations website.

News Market Reaction – UNCY

-0.93%

1 alert

-0.93% News Effect

On the day this news was published, UNCY declined 0.93%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two investor events in September.

Event: H.C. Wainwright 27^th Annual Global Investment Conference
Type: Fireside chat
Date/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET

Event: Truist Securities Virtual Fireside Chat
Date/Time: Wednesday, September 17, 2025, at 10 a.m. ET

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your conference representative.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Investor Contact:

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:
Rachel Visi
Real Chemistry
redery@realchemistry.com

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When is Unicycive Therapeutics (UNCY) presenting at the H.C. Wainwright Conference?

Unicycive's CEO will present at the H.C. Wainwright Conference on Wednesday, September 10, 2025, at 8:30 a.m. ET.

What type of events will Unicycive (UNCY) participate in during September 2025?

Unicycive will participate in two fireside chat events: the H.C. Wainwright Global Investment Conference and the Truist Securities Virtual Fireside Chat.

How can investors access Unicycive's (UNCY) September 2025 presentations?

Investors can access the live and archived webcasts through the Events and Presentations section of Unicycive's website under the Investors section.

What is Unicycive Therapeutics' (UNCY) main focus area?

Unicycive Therapeutics is a clinical-stage biotechnology company developing therapies for patients with kidney disease.